Document Detail

Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects.
MedLine Citation:
PMID:  9112066     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The pharmacokinetics of a single i.v. dose of the new racemic beta-adrenoceptor-blocker nebivolol [0.073 mg ideal body weight (IBW)] was studied in 9 obese (157% IBW) and 9 non-obese healthy volunteers (98% IBW). Each group contained 4 men and 5 women, aged 32 years, including one poor hydroxylator (dextrometorphan test). METHODS: The cardiovascular effects of nebivolol are significant decreases in systolic and diastolic blood pressure, heart rate and cardiac output, which last up to 4-5 h. The plasma concentrations of the separate d- and l- enantiomers of nebivolol, with and without hydroxylated metabolite, were measured by radioimmunoassay and the unchanged racemate by high-pressure liquid chromatography (HPLC). The pharmacokinetic parameters for each form were calculated separately. RESULTS: The main pharmacokinetic parameters of unchanged nebivolol in extensive metabolizers were (controls): distribution volume at steady state (Vss) 673 l; volume corrected by real body weight ( 11.2; total clearance (CL) 51.6 h-1; and terminal half-life (t1/2) 10.3 h. The Vss (898 l) and CL (71.6 l.h-1) were significantly higher in obese patients. But (9.4 and t1/2 (10.0 h) were not significantly different from those in controls. The CL was clearly reduced (15-18 l.h-1) and the t1/2 prolonged (32-34 h) in poor hydroxylators, in both control and obese subjects. The pharmacokinetic parameters of the separate unchanged enantiomers were similar to those of the racemate in both groups. The pharmacokinetics of l-nebivolol were more influenced by the hydroxylation phenotype than those of d-nebivolol. The trend of the results for the sum of each enantiomer plus its metabolite, was similar to those for the unchanged form. CONCLUSION: The distribution of nebivolol in the adipose tissue in obese subjects is limited, despite its high lipophilicity. The differences between obese and non-obese subjects were not clinically relevant.
G Cheymol; R Woestenborghs; E Snoeck; R Ianucci; J P Le Moing; L Naditch; J C Levron; J M Poirier
Related Documents :
11884266 - Obesity-related hypertension: role of the sympathetic nervous system, insulin, and leptin.
20622316 - Simple formulas for screening abnormal blood pressure in children and adolescents.
17426336 - Higher insulin, triglycerides, and blood pressure with greater trunk fat in tanner 1 ch...
19107106 - The role of obesity in the pathogenesis of hypertension.
10474126 - Aldosterone-producing adenoma without hypertension: a report of two cases.
8094936 - Pulmonary hypertension is a contraindication to beta-blockade in patients with severe m...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  51     ISSN:  0031-6970     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  1997  
Date Detail:
Created Date:  1997-06-26     Completed Date:  1997-06-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  493-8     Citation Subset:  IM    
Service de Pharmacologie, Hôpital St Antoine, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / pharmacokinetics*,  pharmacology*
Benzopyrans / pharmacokinetics*,  pharmacology*
Blood Pressure / drug effects
Cardiac Output / drug effects
Chromatography, High Pressure Liquid
Ethanolamines / pharmacokinetics*,  pharmacology*
Heart Rate / drug effects
Lipids / blood
Obesity / metabolism*,  physiopathology*
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Benzopyrans; 0/Ethanolamines; 0/Lipids; 99200-09-6/nebivolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during...
Next Document:  Magnesium pyridoxal-5'-phosphate glutamate, "A vitamin B6 derivative", does not affect lipoprotein l...